SGLT2 Inhibitors – The New HF Therapies on the Block
Published: 25 August 2020
-
Views:
42 -
Likes:
7
-
Views:
42 -
Likes:
7
-
2m 46sPart 1 Welcome & Introductions Subodh Verma
-
20m 55sPart 2 A Brief History of SGLT2 Inhibitors Subodh Verma
-
12m 55sPart 3 What Have We Learned About SGLT2 Inhibitors? A Clinical Perspective Nikolaus Marx
-
9m 55sPart 4 How Might Future Trials Affect How I Treat My Patients? Shelley Zieroth
Overview
In this Educational Symposium from the e-SPACE Heart Failure Global Web-Conference, Subodh Verma, Nikolaus Marx and Shelley Zieroth discuss SGLT2 inhibitors covering their history, a clinical perspective into what we have learned about them and how future trials might affect clinical practice.
Learning objectives
- Raise Awareness of SGLT2 Inhibitors as Cardiovascular Therapies With Cardio–Renal Benefits
- Highlight Appropriate Patients for Initiation of an SGLT2 Inhibitor and Share With Cardiologists the Well-Established Safety Profile and Clinical Considerations for SGLT2 Inhibitor Treatment
- Inform Cardiologists of the Current Evidence and Ongoing Trials for SGLT2 Inhibitors in Patients With HF
Agenda
- 5 mins - Welcome & introduction - Subodh Verma
- 15 mins - A brief history of SGLT2 inhibitors - Subodh Verma
- 15 mins - What have we learned about SGLT2 inhibitors? A clinical perspective - Nikolaus Marx
- 15 mins - How might future trials affect how I might treat my patients? - Shelley Zieroth
- 10 mins - Faculty discussion (pre-recorded) - All Faculty
- Close - Subodh Verma
- Live Q&A and discussion - All Faculty
More from this programme
Part 1
Welcome & Introductions
1 session | |
Welcome & Introductions | Watch now |
Part 2
A Brief History of SGLT2 Inhibitors
1 session | |
A Brief History of SGLT2 Inhibitors | Watch now |
Part 3
What Have We Learned About SGLT2 Inhibitors? A Clinical Perspective
Part 4
How Might Future Trials Affect How I Treat My Patients?
Part 5
Panel discussion
1 session | |
Panel discussion | Watch now |
Faculty Biographies
Subodh Verma
Dr Subodh Verma is a cardiac surgeon-scientist at St. Michael’s Hospital, Professor at the University of Toronto and the Canada Research Chair in Atherosclerosis.
Nikolaus Marx
University Hospital Aachen, Germany
University Hospital Aachen, Germany
Shelley Zieroth
University of Manitoba, Canada
Dr Shelley Zieroth is currently at SBH Heart Failure and Transplant Clinics and serves as Head of the Medical Heart Failure Program, WRHA Cardiac Sciences Program, and as Associate Professor of the Section of Cardiology at the University of Manitoba, Canada.